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Synapse maintenanceCysteine String Protein alpha (CSPα) is a palmitoylated, synaptic vesicle co-chaperone that is essential for
neuroprotection. Two mutations in CSPα — L115R and L116Δ — cause adult neuronal ceroid lipofuscinosis
(ANCL), a dominantly-inherited neurodegenerative disease. To elucidate the pathogenesis of ANCL, the intrinsic
biochemical properties of human wildtype (WT) and disease mutant CSPα were examined. Mutant proteins
puriﬁed from Escherichia coli exhibited high potency to oligomerize in a concentration, temperature, and time
dependent manner, with L115R possessing the greatest potency. When freshly puriﬁed, ANCL mutant proteins
displayed normal co-chaperone activity and substrate recognition similar toWT. However, co-chaperone activity
was impaired for both CSPαmutants upon oligomerization. When WT and mutant CSPα were mixed together
they co-oligomerized leading to an overall decrease of co-chaperone activity. The oligomerization properties of
ANCL mutants were faithfully replicated in HEK 293T cells. Interestingly, the oligomers were covalently tagged
by ubiquitination instead of palmitoylation. Taken together, ANCL mutations result in both a gain and partial
loss-of-function.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Neuronal ceroid lipofuscinoses (NCLs) are inherited, progressive
neurodegenerative diseases that occur mainly in children, and on
occasion, also in adults. They are characterized clinically by gait abnor-
malities, seizures, and dementia. Morphologically, NCLs are identiﬁed
by the lysosomal accumulation of autoﬂuorescent storage material
(lipofuscin) and the loss of neurons, predominantly in the cortex and
cerebellum [1–3]. To date, mutations in 14 genes have been identiﬁed
to cause NCLs [4]. All, but one, CLN4/DNAJC5 encoding amutant Cysteine
String Protein alpha (CSPα), are familially inherited in an autosomal
recessive manner. While the disruption of normal protein function by
nonsense or missense mutations has been demonstrated to underlie
the pathogenesis of autosomal recessive NCL, little has been known
about the unique autosomal dominant form of NCL (CLN4) [5,6].MM149, NewHaven, CT 06536,
, BCMM 154D, New Haven, CT
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g), sreeganga.chandra@yale.eduCSPα is a co-chaperone enriched in the presynaptic terminal. It is
highly conserved among mammals [7] (Fig. 1). CSPα has 3 domains—
an N-terminal J-domain, the middle cysteine string domain which is
palmitoylated on 14 cysteines, and a C-terminal substrate binding do-
main (Fig. 1A). CSPα forms a chaperone complex with Hsc70 and the
tetratricopeptide protein SGT, and plays a crucial role in synapse main-
tenance by acting on select substrates [7–9]. These include SNAP-25 and
dynamin 1, which are essential for synaptic vesicle recycling [10–12].
The two mutations (L115R and L116Δ) that cause ANCL are in the cys-
teine string domain [13–15] (Fig. 1B). As the name indicates ANCL is a
late-onset, dominant form of NCL.
Little is known about the pathogenesis of ANCL. The previousmolec-
ular study on ANCL suggests that the two L115R and L116Δmutations
interferewith palmitoylation of CSPα [16]. Even so, ANCL CSPαmutants
were shown to aggregate in a palmitoylation dependent manner when
heterologously overexpressed with palmitoyltransferases [16]. This
raises the question of how the ANCL mutant proteins intrinsically
behave. In this study, we puriﬁed WT and ANCL mutant CSPα proteins
from Escherichia coli and systemically examined their co-chaperone
activity, dynamics of oligomerization, and subsequently conﬁrmed
these ﬁndings in mammalian cell lines. Remarkably, our results show
that oligomerization of mutant CSPα can occur even in the absence of
palmitoylation and leads to a loss-of-co-chaperone function.
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Fig. 1. Position of ANCL mutations in CSPα. (A) The domain organization and position of ANCL mutations in human CSPα protein. The numbers deﬁne the amino acids that border the
different domains. Amino acid sequence of the Cysteine String Domain is illustrated in detail and the two mutations L115R and L116Δ are indicated by arrows. (B) Alignment of
human, rat, and mouse CSPα protein sequences. Consensus amino acids are marked by black highlights and variable amino acids are indicated by gray and white. The boxes show the
site of ANCL mutant human CSPα and the one difference between the human and mouse sequences.
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2.1. Animals
Allmice are kept according to an IACUC approved protocol in a YARC
mouse colony.
2.2. Materials
Adenosine 5′-diphosphatesodium salt (ADP-Na), adenosine 5′-
triphosphatesodium salt (ATP-Na), 50% hydroxylamine (HA) solution,
and urea were purchased from Sigma. Pfu Turbo DNA polymerase was
purchased from Agilent Technologies. Thrombin was obtained from
GE Healthcare. GenePORTER® 3000 Transfection Reagent was
purchased from Genlantis, while Ni-NTA Agarose was obtained from
QIAGEN. The following primary antibodies were used at the indicated
concentration: CSPα (rabbit, 1:50, Chemicon AB1576), CSPα C terminus
(rabbit, 1:6000, Enzo ADI-VAP-SV003-E), CSPαN terminus (goat, 1:200,
Santa Cruz, N-17), SGT (rabbit, 1:1000, CHAT33), dynamin 1 (rabbit,
1:1000, Epitomics EP801Y), SNAP-25 (mouse, 1:20,000, Sternberger
Monoclonals Inc. SMI-81), α-synuclein (rabbit, 1:1000, T2270), ubiqui-
tin (mouse, 1:1000, LifeSensor, FK2), FLAG (rabbit, 1:1000, Sigma,
F7425), and Myc (Mouse, 1:1000, Thermo Scientiﬁc, A7).
2.3. Site-directed mutagenesis
Site-directed mutagenesis was performed using QuickChangeTM
Site-directed Mutagenesis kit (Stratagene). The primers for the
mutagenesis were as follows:
Rat CSPα cDNA to cDNA encoding human CSPα;
Sense: 5′-CAAGGCGCTGTTCGTC(G/T)TCTGTGGCCTCCTCAC;
Antisense: GTGAGGAGGCCACAGA(C/A)GACGAACAGCGCCTTG;L115R mutation:
Sense: 5′-TTCGTCTTCTGTGGCC(T/G)CCTCACCTGCTGCTAC;
Antisense: 5′-GTAGCAGCAGGTGAGG(A/C)GGCCACAGAAGACGAA.
L116Δmutation:
Sense: -TCGTCTTCTGTGGCCTC(CTC/Δ)ACCTGCTGCTACTGCTG;
Antisense: 5′-CAGCAGTAGCAGCAGGT(GAG/Δ)GAGGCCACAGAAGA
CGA.
For insertion of stop codon TAA downstream base pair 408 to delete
‘C’ terminus of CSPα:
Sense: 5′-CTGCTGTGGGAAGTGC(TAA)AAGCCCAAGGCACCTG.
Antisense: 5′-CAGGTGCCTTGGGCTT(TTA)GCACTTCCCACAGCAG.
The italic letters in brackets indicate the original nucleotides. The
ampliﬁed mutant plasmids were conﬁrmed by sequencing.
2.4. Construction of plasmids
All site-directed mutagenesis were performed on CSPα sequences
subcloned into either PGEX-KG or lentiviral expression plasmids. To in-
sert Myc or FLAG tags upstream of CSPα in lentiviral expression plas-
mids, XbaI was used to excise the vector and ligated with the
annealed oligonucleotides encoding Myc or FLAG. The start codon ATG
of CSPα was then removed by site-directed mutagenesis as above. The
inserted oligonucleotides are as follows:
Myc: Sense 5′-CTAGAATGGAACAAAAACTTATTTCTGAAGAAGATC
TG;
Antisense 5′-CTAGCAGATCTTCTTCAGAAATAAGTTTTTGTTCCATT;
FLAG: Sense 5′-CTAGAATGGATTACAAGGATGACGATGACAAG;
Antisense 5′-CTAGCTTGTCATCGTCATCCTTGTAATCCATT.
The primers for site-directed mutagenesis are as follows:
Myc-CSPα ATG deletion:
2138 Y. Zhang, S.S. Chandra / Biochimica et Biophysica Acta 1842 (2014) 2136–2146Sense: 5′-GAAGATCTGCTAGAC(ATG/Δ)GCTGACCAGAGGCAG;
Antisense: 5′-CTGCCTCTGGTCAGC(CAT/Δ)GTCTAGCAGATCTTC.
FLAG- CSPα ATG deletion:
Sense: 5′-CGATGACAAGCTAGAC(ATG/Δ)GCTGACCAGAGGCAGC;
Antisense: 5′-GCTGCCTCTGGTCAGC(CAT/Δ)GTCTAGCTTGTCATCG.
To generate the J domain deletion CSPα construct an XbaI restriction
site with an additional a nucleotide C was inserted downstream base
pair 246 of CSPα PGEX-KG plasmid by site-directed mutagenesis. The J
domain fragment was excised out by XbaI digestion and the ﬁnal
CSPα construct without the J domain was obtained by a subsequent
re-ligation. The primers for site-directed mutagenesis are as follows:
Sense: 5′-CAAGTATGGCTCGCTG(TCTAGAC)GGGCTCTATGTGGCTG;
Antisense: 5′-CAGCCACATAGAGCCC(GTCTAGA)CAGCGAGCCATA
CTTG.
All clones were conﬁrmed by sequencing.
2.5. Protein puriﬁcation
GST-Hsc70, GST-WT, and mutant GST-CSPα were expressed in
BL21(DE3) E. Coli and puriﬁed as previously described [12]. GST tags
were cleaved with thrombin and removed by afﬁnity chromatography.
His tagged SGTwas puriﬁed usingNi-NTA agarose beads based on the de-
scription in the manual (QIAGEN). To prevent disulﬁde bond formation,
2 mM TCEP or DTT was added to the puriﬁed proteins. The concentration
of the protein preparationswas obtained spectrophotometrically. Puriﬁed
protein was aliquoted and stored at−80 °C before use.
2.6. Immunoblotting
Equal amounts for puriﬁed proteinwere loaded for SDS-PAGE, while
for HEK 293 T cell lysates equal volumeswere loaded. The proteinswere
probed ﬁrst with speciﬁc primary antibodies and then with IRDye
conjugated secondary antibodies. Protein bands were quantiﬁed on a
LI-COR Odyssey infrared imaging system. All CSPα bands over 53 kDa
were selected and quantiﬁed as HMW oligomers.
2.7. ATPase assay
ATPase activity was assayed using a colorimetric approach as de-
scribed by Chamberlain and Burgoyne [17]. Prior to the start of the
ATPase assay, 40 μM of puriﬁed WT and mutant CSPα (or a mixture of
20 μM of each) was pre-warmed for 1 min or for 24 h at 37 °C. Puriﬁed
protein (1 μmol)was incubated in ATPase assay buffer (10mMMgCl2, 5
mM KCl, 50 mM Tris, pH 7.5) for 5 min, followed by addition of 1 mM
ATP to start the reaction. Aliquots (10 μL) of the reaction were with-
drawn every 4 min and incubated with 800 μL of MG solution (0.034%
malachite green, 1.04% NH4-molybdate, 1 M HCl, 0.04% Tween-20) for
1 min and quenched with 100 μL of 34% Na-citrate. OD650 was
measured 5 min after quenching. The experiment was calibrated using
1 mM KH2PO4 and the concentration of free phosphate was calculated
based on the equation 1OD650 = 9.45 nmol Pi.
2.8. GST pull-down
WT or ANCL mutant GST-CSPα fusion proteins were puriﬁed from
E. coli as described [12]. Fusion protein bound to beads was mixed
with brain extract (in 20 mM HEPES, pH 7.4, 100 mM NaCl, 1% Triton
X-100) and incubated for at least 4 h by rotating at 4 °C. Depending
on experimental condition, 5 mMADP or ATPwas added to themixture
as noted. The beads were then washed 3 times for 10 min with HEPES
buffer containing 1% Triton X-100 and ﬁnally eluted with SDS-PAGE
sample buffer by boiling for 10 min.2.9. Immunoprecipitation
HEK 293T cells expressingWT ormutant CSPαwere lysed in IP buff-
er [20 mM HEPES, pH 7.4, 100 mM NaCl, 2 mM CaCl2, 1 mMMgCl2, 1%
Triton X-100, 1 mM PMSF, pepstatin (1 μg/mL), aprotinin (2 μg/mL),
leupeptin (1 μg/mL)] and rotated for overnight at 4 °C. The lysate was
spun for 15 min at 11,300 g and the supernatant was pre-cleared by
incubating with washed Protein A with rotation for 1 h at 4 °C. The
pre-cleared supernatant was incubated with the denoted antibody for
1 h at 4 °C and then with washed Protein A beads for 1.5 h at 4 °C.
The beads were then washed ﬁve times with 1 mL of IP buffer, and the
bound proteins were eluted by boiling 10 min in SDS-PAGE sample
buffer.
2.10. Cell culture and transfection
HEK 293T cells were maintained in DMEM supplemented with 10%
FBS and 1% penicillin/streptomycin and grown to 80% conﬂuency in
25 cm2 ﬂasks. Cells were split into 6-well dishes and transfected using
GenePORTER3000 lipid reagent, based on the provided protocol.
Protein was harvested 48 h after transfection in homogenization
buffer [(20 mM HEPES, pH 7.4, 100 mM NaCl, 1 mM PMSF, pepstatin
(1 μg/mL), aprotinin (2 μg/mL), leupeptin (1 μg/mL), 1% Triton X-100)].
2.11. Statistics
All values are presented as the mean ± SEM, and p b 0.05 was con-
sidered statistically signiﬁcant. Calculations were performed using the
GraphPad Prism 4 software (San Diego, CA).
3. Results
3.1. Intrinsic oligomerization of CSPαmutants
We generated ANCL mutants by site-directed mutagenesis (Fig. 1)
and characterized the biochemical properties of these proteins. As the
ANCL mutations abolish palmitoylation of CSPα [14,16], we decided to
explore the inherent properties of WT and mutant human CSPα
proteins without lipid posttranslational modiﬁcations. WT and ANCL
mutant CSPα proteins were overexpressed in BL21(DE3) E. coli, which
like all bacterial strains lack the eukaryotic palmitoyltransferase
enzymes needed to covalently attach palmitates to cysteine residues.
Puriﬁed proteins (1 mg/mL) were subject to SDS-PAGE in the presence
of 50mMof DTT as previous studies have showed that oligomers ofWT
CSPα are SDS-resistant [18]. Coomassie staining and immunoblotting of
puriﬁed proteins indicated that the protein purity exceeded 95%
(Fig. 2A, D). The gels show that both L115R and L116Δ mutants
exhibit noticeable oligomerization compared with the WT CSPα
(Fig. 2A, B, D, E). Strikingly, oligomerization occurred even in the
presence of 1000 fold molar excess reducing agent, suggesting that it
is not due to the formation of disulﬁde bonds by the unpalmitoylated,
free cysteines (Fig. 2A, D; Fig. S1). In the absence of DTT, both WT and
mutant CSPα show a similar protein smear-like pattern as would be
expected fromnon-speciﬁc disulﬁde bond formation (Fig. S1). The addi-
tion of DTT abolished the smear except for the speciﬁc oligomers seen in
the case of ANCL mutants (Fig. S1).
Distinct oligomeric species were seen with the two ANCL mutants.
The size of the oligomers for the L115R mutant were ~56, ~100 and
~250 kD, corresponding to dimer, tetramer and species with 8 or
more monomers, while the size of the oligomer for the L116Δmutant
was ~250 kD (Fig. 2A, D). The dissimilar banding pattern suggests that
the oligomerization behavior of L115R and L116Δ is different, but gen-
erates at least one common oligomeric ~250 kD species. As shown in
Fig. 2E, the L115R mutant also produced higher molecular weight
(HMW) oligomers (58.9 ± 5.9 fold versus WT) than the L116Δmutant
(13.2 ± 3.9 fold versus WT). In the case of L115R, oligomerization was
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Fig. 2. Oligomerization of puriﬁed ANCLmutant CSPα proteins. (A) Coomassie staining of puriﬁedWT andmutant CSPα protein (5 μg). (B, C) Quantiﬁcation of highmolecular weight (HMW)
oligomers andmonomers shown in (A). (D) Immunoblotting of puriﬁedWTandmutant CSPαprotein (1 μg). (E, F)Quantiﬁcation ofHMWoligomers andmonomers shown in (D), respectively.
The ﬁlled arrow indicates themonomer. #: contaminant band. The results are from three experiments and the quantiﬁcation is expressed as average±SEM. *p b 0.05; **p b 0.01; ***p b 0.001;
NS: Not signiﬁcant.
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fold versus WT; Fig. 2C and F). Taken together, both CSPαmutants are
prone to oligomerize and form HMW oligomers which were DTT
resistant, but the L115Rmutant has the highest propensity to do so. Im-
portantly, the oligomerization occurs in the absence of palmitoylation.
Given that both ANCL mutations are located in the proximity of
cysteine string domain, we investigated whether the ﬂanking domains,
i.e. the J domain and C terminus (Fig. 1A; Fig. S2A), affect the oligomer-
ization of CSPαmutants. We generatedWT andmutant, J domain and C
terminus deletions, and conﬁrmed that we successfully deleted the
relevant domains by staining with CSPα N terminus and C terminus
epitope speciﬁc antibodies (Fig. S2C, D). As shown in Fig. S2, neither
deletion of the J domain nor C terminus inhibits the oligomerization of
the ANCL mutants (Fig. S2B, F). In fact, the deletion of the J-domain
increased the abundance of oligomers for both WT and ANCL CSPα
(Fig. S2B, D and E), indicating a possible inhibitory role. Overall, these
data suggest that the cysteine string domain and the ANCL mutations
are the key determinants of CSPα oligomerization. Our ﬁndings are
consistent with the previously published results showing that amino
acids 83–138 of WT CSPα, which include the cysteine string domain
are important for self-assembly [18].
Next, we examined whether SGT, a clamp protein that stabilizes the
CSPα/Hsc70 chaperone complex, played a signiﬁcant role in oligomeri-
zation of ANCLmutants [7]. Surprisingly, SGT exhibited no effect on olig-
omerization of CSPα mutants (Fig. S3), and furthermore SGT was not
observed to assemble into CSPα oligomers (Fig. S3A, B and D). These
data suggest that oligomerization is an intrinsic protein property of
ANCL mutant CSPα.
3.2. Characterization of oligomerization properties of mutant CSPα
For familiar neurodegenerative disease proteins such as Aβ and
α-synuclein, it has been well established that increased proteinconcentration accelerates oligomerization and aggregation of mutant
proteins [19,20]. To test whether CSPα behaved similarly, we prepared
solutions of increasing protein concentrations (0.125–1.0 mg/mL; 5–
40 μM) and subject them to SDS-PAGE and immunoblotting. Fig. 3A–C
shows that raising protein concentration signiﬁcantly augmented
HMW oligomers and reduced monomer amounts for L115R. The three
dominant species showed different concentration dependence with
the ~100 and ~250 kD species exhibiting a signiﬁcant increasewith con-
centration (Fig. S4)while the ~56 kDdid not, suggesting that the species
N100 kD arise frommonomers directly (Fig. S4). For the L116Δmutant,
we only observe the formation of the 250 kD species at a concentration
of 1 mg/mL (Fig. 3A, B) and the monomer levels displayed a mild
decrease compared with WT (Fig. 3C).
Another property for neurodegenerative associated proteins is their
temperature dependence of oligomerization and aggregation [21]. Since
the above western blots were performed after boiling the samples, two
other temperatures, 37 °C and 69 °C, were chosen to treat the proteins
prior to separation on SDS-PAGE. As seen in Fig. 3D–F, oligomeric inter-
mediates were formed for L115R at all temperatures tested. Interesting-
ly, WT and L116Δ form novel oligomeric species at 37 °C, several of
which are shared with L115R, but these intermediates are abolished
with the exception of the 250 kD species, upon increasing the tempera-
ture (Fig. 3D). Consistent with this, the monomer levels were increased
as a function of temperature, reﬂecting an imbalance between the
disassembly of non-speciﬁc oligomers and formation of mutant speciﬁc
species (Fig. 3F and Fig. S1). The quantiﬁcation of the CSPα band at
250 kD reveals that its levels increase with temperature for both
mutants (Fig. 3E). The temperature dependence mirrors the concentra-
tion dependence of oligomer formation for the two ANCL mutants
(Fig. 3B, E), again indicating different propensity to oligomerize.
To investigate this further, we varied the time of incubation at 37 °C.
As shown in Fig. 3G–I, both mutants formed oligomers in a time-
dependent manner, though the L116Δ has a longer lag. A noteworthy
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proteins at 37 °C for 24 h mimics that at 100 °C for 10 min (Fig. 3G
versus Fig. 2D). In these samples, the 250 kD species predominates
indicating that this is a physiologically relevant species. We also did
not observe macroscopic aggregates. In all, our data support the princi-
ple that oligomerization of CSPαmutants, like other neurodegenerative
disease proteins, is concentration and time-dependent.
3.3. Co-chaperone function is impaired by oligomerization of CSPαmutants
CSPα functions as co-chaperone through its interactions with Hsc70
and its substrates [7,12]. We wanted to explore whether the ANCL
mutations impact co-chaperone function of CSPα directly or indirectly
through increased protein oligomerization. First, we determined the
effect of ANCL mutations on freshly puriﬁed protein preparations
which have equivalent amounts of monomeric proteins (Fig. 4A–D).
We measured the ability of the CSPαmutants to accelerate the ATPase
activity of Hsc70, via their J-domains. WT CSPα can readily accelerate
the basal ATPase activity of Hsc70 by 2.5 fold consistent with the
previously published results (Fig. 4A) [12,22]. As a negative control,
we used a J-domain mutant (CSPα QPN) which has diminished Hsc70binding and impaired ability to stimulate the ATPase activity of Hsc70
[12]. Remarkably, both the L115R and L116Δ mutants could robustly
accelerate the ATPase activity of Hsc70 to the same level as WT protein
(Fig. 4A, D). These enzymatic assay results indicate that the J-domain of
the ANCLmutants can bind Hsc70 and is functional. Next, we examined
the functionality of the C-terminal domain by assessing the ability of the
ANCL mutants to bind speciﬁc CSPα clients. We tested binding to the
two best characterized clients of CSPα—SNAP-25 and dynamin 1 [11,
12] by performing afﬁnity chromatography using mouse brain homog-
enates. These experiments clearly demonstrate that the ANCL mutants
can bind client proteins as effectively as WT CSPα (Fig. 4E). This
biochemical interrogation revealed that ANCL CSPα mutants, when
not oligomerized, are functional as co-chaperones. This is consistent
with the fact that both ANCL mutations are in cysteine string domain
and not in the J- or C-terminal domain.
To study the impact of oligomerization on CSPα co-chaperone activ-
ity, we incubatedWT and ANCLmutant CSPα for 24 h at 37 °C, followed
by Hsc70 ATPase assays. The L115R mutant's ability to stimulate Hsc70
ATPase activity was dramatically reduced by 80%, but no signiﬁcant
difference was observed for the L116Δ mutant compared with WT
(Fig. 4F). The co-chaperone capacity of these protein preparations
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of L115R but still 66% of L116Δmonomerwas left after 24 h (Fig. 4G, H).
Nonetheless, the decrease in monomer levels is more affected than
enzymatic activity, and can be seen by normalizing ATPase activity to
CSPα monomers amount (Fig. 4I). This implies that perhaps dimeric
CSPα species retain ATPase stimulatory activity as suggested previously
[17], while other HMW oligomers are not functional.
3.4. Co-oligomerization of WT and mutants attenuates co-chaperone
activity of CSPα
ANCL occurs in the heterozygous statewith one copy each ofWT and
mutant CSPα. To model the disease condition, we mixed WT and ANCL
mutants in a 1:1M ratio (0.5 mg/mL), and incubated the proteins for 24
h at 37 °C.Weﬁrst examined the oligomeric proﬁles of themixtures andcompared it to the individual proteins. Intriguingly, both ANCL mutants
whenmixedwithWT protein formed the 250 kDa species, even though
both WT and L116Δ individually did not do so under these lower pro-
tein conditions (Fig. 5A). Quantiﬁcations conﬁrmed that the WT:ANCL
mixtures do indeed oligomerize to a greater extent (Fig. 5B) and are ac-
companied by a larger loss of monomer (Fig. 5C). Next, we used these
mixtures to test their efﬁcacy in the Hsc70 ATPase assays and compared
them to the same proteins incubated alone. We observed that ATPase
activity of the mixtures was signiﬁcantly lower than what one would
expect from the sum of the individual protein activity (Fig. 5D). This
would suggest that the mixtures oligomerize to a greater extent and
that hetero-oligomers of WT and ANCL mutants are not enzymatically
active. It is important to note that both the L115R and L116Δmutants
behave similarly in the presence ofWTprotein, consistentwith the sim-
ilar phenotypes seen in patients.
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Our experiments using puriﬁed proteins suggest that oligomeriza-
tion is an intrinsic property of ANCL CSPα mutants. This raises the
question whether this is purely an in vitro phenomenon or could also
occur in mammalian cells. To examine this matter, WT and the ANCL
proteins were overexpressed in HEK 293T cells. Cell lysates were
incubated at 37 °C, separated on SDS-PAGE and blotted for CSPα
(Fig. 6A–C). Both ANCL mutants exhibited observable oligomerization,
(Fig. 6A), resembling the puriﬁed proteins in vitro (Fig. 1A, D). Consis-
tent with the puriﬁed protein data (Fig. 2), all oligomeric intermediates
shifted to the top of the gel when the samples were boiled (Fig. 6D–F).
In HEK 293T cells, the palmitoylation of monomers was severely
impaired for the ANCLmutants (Fig. 6A, D; S5) in line with previous re-
ports [16]. To test if the oligomers were palmitoylated, an aliquot of the
same HEK 293T cell lysate was treated overnight at 4 °C with
hydroxylamine (HA), a chemical that depalmitates proteins. A slight
decrease in oligomers and increase of monomers were detected for
the L115R (0.9 ± 0.016 fold of HMW/monomer versus ‘No HA’) and
L116Δ mutants (0.95 ± 0.02 fold of HMW/monomer versus ‘No HA’)(Fig. 6F), with only a few selected bands disappearing upon hydroxyl-
amine treatment, even though theWTmonomeric CSPαwas complete-
ly depalmitoylated under these conditions (Fig. 6A, D). This suggests
that in HEK 293T cells, ANCL CSPα oligomers were largely not
palmitoylated. Next, we tested if the soluble oligomers formed insoluble
macroscopic aggregates, as seen in other dominantly inherited neuro-
degenerative diseases. Pellet fractions from transfected HEK 293T cells
were subject to centrifugation steps to enrich for aggregates and solubi-
lized in 8 M urea containing sample buffer. Neither monomer nor
oligomer was present in the pellet (data not shown), suggesting no in-
soluble aggregates were formed. This ﬁnding is congruent with the lack
of overt CSPα neuropathology in ANCL brains [14]. The similarity of
oligomerization of CSPαmutants both in vitro and in mammalian cells
indicates that CSPα oligomers are indeed newly gained species in ANCL.
3.6. Co-oligomerization ofWT andmutantswhen co-expressed inHEK293T
cells
Our in vitro experiments using mixtures of WT and mutant CSPα
protein demonstrated an overall increase in oligomerization and
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cannot exclude that the oligomers are derived only from the mutant
rather than from both WT and mutant. To test whether the ANCL
mutant proteins are capable of forming mixed oligomers with the WT
protein, we used FLAG and Myc tagged CSPα constructs and co-
expressed them in HEK 293T cells. Western blotting with FLAG or Myc
antibody conﬁrmed that the tagged proteins behave similar to untagged
versions, with the ANCL mutants forming 250 kD oligomers to a greater
extent thanWTCSPα (Fig. 7A, B, E, F versus Fig. 6D, E). The co-expression
of Myc taggedWTwith FLAG taggedmutant and vice versa signiﬁcantly
promoted the formation of WT oligomers (Fig. 7C, D, G, H), indicating
the formation of mixed oligomers.3.7. Ubiquitination of oligomers formed by both WT and mutant CSPα
The aboveHEK 293T experiments establish that the ANCLmutants are
not palmitoylated and readily oligomerize compared toWTCSPα (Fig. 6).
Based on theseﬁndings, we testedwhether CSPα oligomers are selective-
ly targeted for degradation. CSPα proteins were immunoprecipitated
from HEK 293T cell lysates and probed with an antibody that recognizes
poly-ubiquitination, a covalentmodiﬁcation that targets proteins for deg-
radation. As shown in Fig. 8A, CSPα antibody could immunoprecipitate
and enrich both monomers and oligomers. Fascinatingly, the poly-
ubiquitin antibody only signiﬁcantly recognized the 250 kD band whose
signal intensity correlated with the amount of CSPα positive oligomers
(Fig. 8B, C).4. Discussion
4.1. Gain and loss of function mechanisms underlie ANCL
In this study, we systemically characterized the two ANCL causing
mutants—L115R and L116Δ. Unlike other recessive NCL mutations
which directly abrogate the normal function of the associated proteins,
dominant CSPαmutations had no adverse effect on CSPα co-chaperone
activity and substrates binding afﬁnity, instead they drove the forma-
tion of novel oligomeric species which in turn disrupted the function
of bothWT andmutant CSPα. Herewe propose that the oligomerization
of CSPαmutants is a gain-of-function which directly leads to a loss-of-
function based on several observations. 1) The oligomerization of
ANCL CSPα mutants occurs extensively and in a time, concentration,
and temperature dependent manner (Fig. 3). 2) The loss of co-
chaperone activity of mutant CSPα depends on protein oligomerization.
In the absence of oligomerization,WT andmutant stimulate ATPase ac-
tivity of Hsc70 equivalently (Fig. 4A); indicating that the mutation itself
does not affect the inherent function of CSPα. Further, the decrease in
CSPα co-chaperone activity largely reﬂects the loss of monomers by
oligomerization (Fig. 4F–H). 3) The co-oligomerization of WT and
mutants occurs both in vitro and in mammalian cells (Figs. 5, 7). There-
by, co-oligomerization makes it feasible for one mutant CLN4/DNAJC5
allele to result in the dysfunction of CSPα protein encoded by both
alleles and most likely accounts for the dominant nature of ANCL. 4)
In support of a loss-of-function mechanism, we observe mislocalization
of both WT and mutant CSPα in the cell body away from synaptic
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ﬁndings point to ANCL operating in a dominant negative manner.
While oligomerization is a commonmolecular feature of autosomal-
dominant inherited neurodegenerative diseases—such as Alzheimer's
disease, Parkinson's disease, and ALS—for these diseases oligomeriza-
tion does not appear to result in a loss-of-function. This is supported
by the fact that the deletion of the corresponding disease causing
genes—APP, α-synuclein and superoxide dismutase 1—from mice
genome results in no or subtle phenotype [23–25], unlike patients or
transgenic mice that overexpress mutant proteins [26–28]. One domi-
nant neurodegenerative disease clearly shown to be caused by both a
gain and partial loss-of-function is spinocerebellar ataxia 1 [29]. Muta-
tions in ataxin 1 cause spinocerebellar ataxia 1, but do not involve
protein oligomerization. Inmarked contrast to these neurodegenerative
diseases, in ANCL, an oligomerization dependent loss-of function is like-
ly to underlie its pathogenesis as CSPα knockoutmice phenocopy ANCL
patients. CSPα knockoutmice showprogressive neurodegeneration and
exhibit phenotypes such as seizures, motor deﬁcits, and premature
death seen in patients. Our data adds to growing evidence that for
dominantly inherited neurodegenerative diseases, multiple mecha-
nisms of action are likely to underlie disease pathophysiology.
Thoughwe have clearly demonstrated an oligomerization-dependent
loss of CSPα co-chaperone activity, it remains possible that the oligomers
have additionalmodes of action. CSPα is a synaptic vesicle associated pro-
tein which is synthesized in endoplasmic reticulum (ER), transported to
synaptic terminal via the Golgi and degraded in lysosomes [30]. Consider-
ing the stringent protein quality control that occurs at the ER, a question
that remains to be addressed iswhether oligomerization of CSPαmutants
also causes ER stress and subsequently the unfolded protein response [31,
32]. Similarly, possible deleterious effect of oligomers on Golgi and lyso-
somes needs more investigation. However, these studies are beyond the
scope of the present work.
4.2. Distinct oligomerization pathways for L115R and L116Δ mutants
Although the L115R and L116Δmutations are localized to cysteine
string domain and even are next to each other, previous in silico analysis
had predicted dissimilar alterations on biophysical and biochemical
properties of CSPα. In keeping with this, we see clear differences in
the oligomerization behavior for the L115R and L116Δ mutants both
in terms of magnitude and time dependence. The L115R mutant was
predicted to have aweakermembrane afﬁnitywhich possibly facilitates
self-assembly. Consistent with this prediction, we demonstrate thatL115R is more potent to oligomerize than L116Δ. Interestingly, L115R
patient brains have been shown to have less CSPα protein levels com-
pared to L116Δ brains [14]. The two mutants also differ in the dynamic
pattern of oligomerization. The L116Δ mutant resembles the WT
oligomer pattern but with a higher abundance, in contrast, the L115R
oligomer pattern clearly varies from WT and L116Δ (Fig. 3D, G;
Fig. 4B, G; Fig. S2B; Fig. S3C). Yet, both mutants generate at least one
common 250 kDa oligomeric species, strongly suggesting that this
may be a disease relevant oligomer.
Interestingly, the co-oligomerization of L115R and L116ΔwithWT is
very similar, in spite of the different potentials for self-assembly. As a
consequence, L116Δ appears to be more potent than L115R to co-
oligomerize with WT CSPα. On the other hand, L115R oligomerization
stands out with respect to its ability to self-assemble. Hence, we predict
that ANCL patients carrying differentmutants might show subtle differ-
ences in age of onset, speed of progress and duration of disease.
4.3. Post-translational modiﬁcations on ANCL mutants
Both ANCL mutations abolish palmitoylation of monomeric CSPα in
HEK 293T cells. This is most likely because the leucines mutated in
ANCL are needed to target CSPα to the membrane allowing the
palmitoylacyltransferases to palmitoylate CSPα [33]. Our ﬁndings on the
impact of ANCLmutations on palmitoylation are congruentwith those re-
ported by Greaves et al. [16]. However, in contrast to the reported work,
we do not ﬁnd any effect of palmitoylation on protein oligomerization.
This may be due to the fact that palmitoylacyltransferases were
overexpressed to make this point [16]. The fact that recombinantly pro-
duced protein from E. coli which lack palmitoylation also aggregates
strongly support our case that palmitoylation is not required for ANCL
mutant oligomerization. In contrast to a role for palmitoylation, we ob-
served that the 250 kD oligomer is selectively ubiquitinated. It is widely
accepted that ubiquitination can serve as a signal for degradation of lyso-
somes [34]. Hence, we hypothesize that the degradation of CSPα oligo-
mers via lysosomes over time leads to lysosomal dysfunction and
lipofuscin deposition.
5. Conclusion
Here we provide the evidence that ANCL mutants, CSPα L115R and
L116Δ, could undergo self-oligomerization and co-oligomerization
withWT CSPα. Oligomerization is therefore a gain-of-function as result
of these mutations, but leads to a loss of co-chaperone activity of CSPα.
2146 Y. Zhang, S.S. Chandra / Biochimica et Biophysica Acta 1842 (2014) 2136–2146Hence, we propose a mechanism involving both a gain-of-function and
a loss-of-function of CSPα causes ANCL. Our ﬁndings are congruentwith
the fact that ANCL is a dominant disease and helps explain the pheno-
types seen in CLN4 patients. Altogether, our data highlight the role of
protein oligomerization in ANCL and suggest that disrupting oligomeri-
zation of CSPαmutants may be an effective therapy for treating ANCL.
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